We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+14.73%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$80.2M
Cap. Flow
+$76.6M
Cap. Flow %
21.79%
Top 10 Hldgs %
34.86%
Holding
100
New
24
Increased
44
Reduced
21
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14M
2
LLY icon
Eli Lilly
LLY
+$11.2M
3
EW icon
Edwards Lifesciences
EW
+$7.88M
4
HAE icon
Haemonetics
HAE
+$6.52M
5
CVS icon
CVS Health
CVS
+$6.34M

Top Sells

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$7.01M
2
ALT icon
Altimmune
ALT
+$6.55M
3
AVTR icon
Avantor
AVTR
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.07M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Industrials 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$23.1B
$17.2M 4.9%
82,270
-9,536
-10% -$2.13M
UNH icon
2
UnitedHealth
UNH
$370B
$14M 3.97%
27,641
-1,170
-4% -$615K
DHR icon
3
Danaher
DHR
$144B
$13.7M 3.89%
59,791
+16,401
+38% +$4.02M
BSX icon
4
Boston Scientific
BSX
$71.5B
$13.5M 3.83%
+347,787
New +$14M
NBIX icon
5
Neurocrine Biosciences
NBIX
$16.6B
$12.5M 3.55%
117,400
+31,811
+37% +$3.23M
LLY icon
6
Eli Lilly
LLY
$1.06T
$11.4M 3.24%
+35,285
New +$11.2M
CVS icon
7
CVS Health
CVS
$122B
$11.2M 3.19%
117,634
+64,087
+120% +$6.34M
IONS icon
8
Ionis Pharmaceuticals
IONS
$9.4B
$10.7M 3.04%
241,945
+67,645
+39% +$2.85M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$9.91M 2.82%
72,397
-4,229
-6% -$689K
HAE icon
10
Haemonetics
HAE
$4B
$8.57M 2.44%
115,797
+90,797
+363% +$6.52M
THC icon
11
Tenet Healthcare
THC
$21.1B
$8.2M 2.33%
159,024
+66,834
+72% +$3.97M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.12B
$8.04M 2.28%
222,597
-71,962
-24% -$2.59M
ELV icon
13
Elevance Health
ELV
$85.5B
$7.81M 2.22%
17,196
-554
-3% -$265K
CDMO
14
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$7.74M 2.2%
404,818
-56,408
-12% -$1.03M
CNCE
15
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.62M 2.17%
1,137,587
+13,515
+1% +$81.9K
WAT icon
16
Waters Corp
WAT
$39.9B
$7.45M 2.12%
27,630
+1,380
+5% +$440K
CTIC
17
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.04M 2%
1,210,145
+159,098
+15% +$991K
EW icon
18
Edwards Lifesciences
EW
$51.7B
$6.77M 1.92%
+81,906
New +$7.88M
IQV icon
19
IQVIA
IQV
$39.3B
$6.37M 1.81%
35,171
-4,530
-11% -$992K
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.58M 1.59%
+301,892
New +$4.74M
RCM
21
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.16M 1.47%
278,486
+48,073
+21% +$1.1M
LEGN icon
22
Legend Biotech
LEGN
$4.01B
$4.95M 1.41%
121,227
+3,420
+3% +$161K
ATEC icon
23
Alphatec Holdings
ATEC
$1.44B
$4.76M 1.35%
545,133
+21,398
+4% +$169K
NTRA icon
24
Natera
NTRA
$46.4B
$4.61M 1.31%
105,201
+31,154
+42% +$1.48M
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$7.96B
$4.61M 1.31%
+187,989
New +$3.5M
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Parkman Healthcare Partners held 100 positions worth $352M, up 30% from $272M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners deployed $76.6M of net new capital in Q3 2022, opening 24 new positions and adding to 44 existing holdings. Its largest new stake was Boston Scientific: 347,787 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was iRhythm Holdings, an estimated $7.01M trimmed.

  • Parkman Healthcare Partners's largest Q3 2022 buy was Boston Scientific: 347,787 shares worth $13.5M.
  • Parkman Healthcare Partners added most to Haemonetics in Q3 2022, an estimated $6.52M increase.
  • Parkman Healthcare Partners's biggest Q3 2022 reduction was iRhythm Holdings, cutting an estimated $7.01M.
  • Parkman Healthcare Partners fully exited Altimmune in Q3 2022, selling an estimated $6.55M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $352M portfolio in Q3 2022.
  • Parkman Healthcare Partners opened 24 new positions and closed 11 in Q3 2022.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $352M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.